····_ • · ..., 💂

3 O 2003

PART B - FEE(S) TRANSMITTAL

nd send this form, together with applicable fee(s), to: Mail Complete

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (703) 746-4000

or Fax

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

7590

12/18/2003

VERTEX PHARMACEUTICALS INC. 130 Waverly Street Cambridge, MA 02139-4242

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Malling or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

(Depositor's name) Karen DiRoceo men (Signature) December 30 2003 (Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/071.699	02/08/2002	Jingrong Cao	VPI/01-103 US	2092

TITLE OF INVENTION: HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF

APPLN. TYPE	SMALL ENTITY ISSU		Œ	PUBLICATION FEE	TOTAL	FEE(S) DUE	DATE DUE	
nonprovisional	nonprovisional NO \$13		0 \$300		2	1630	03/18/2004	
EXAM	IDNER	ART UNI	п	CLASS-SUBCLASS				
RAO, DEEPAK R		1624		514-235800	·			
1. Change of correspondenc CFR 1.363). Change of corresponde Address form PTO/SB/1: "Fee Address" indicate PTO/SB/47; Rev 03-02 of Number is required.	Correspóndence	2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.						
PLEASE NOTE: Unless	RESIDENCE DATA TO B an assignee is identified be d to the USPTO or is being s EE	ow, no assignee da	nta will appear or parate cover. Com	the patent Inclusion	s NOT a substitute	is only appropri for filing an ass	ate when an assignment has	
Vertex Pharm	aceuticals Inco	rporated		Cambrio	lge, MA (2139		
Please check the appropriate	assignee category or catego	ries (will not be pri	nted on the paten	t); 🖸 individual	n corporation o	r other private gr	oup entity 🚨 government	
4a. The following fee(s) are	enclosed:	4b.	Payment of Fee	s):				
Issue Fee			☐ A check in the amount of the fee(s) is enclosed.					
Publication Fee		•	☐ Payment by credit card. Form PTO-2038 is attached.					
Advance Order - # of	Copies Ten (10)		The Director Deposit Account	is hereby authorized Number 50-07	by charge the rec	quired fec(s), or nelose an extra c	credit any overpayment, to opy of this form).	
Director for Patents is reque	sted to apply the Issue Fee at	nd Publication Fee ((if any) or to re-a	pply any previously	paid issue fee to th	e application ide	ntified above.	
other than the applicant; interest as shown by the re- This collection of informa obtain or retain a benefit application. Confidentiality estimated to take 12 minut completed application for case. Any comments on suggestions for reducing the patent and Trademark (22313-1450, DO NOT S.)	I Production Fee (if require a registered attorney or age cords of the United States Pation is required by 37 CFR by the public which is to five governed by 35 U.S.C. I es to complete, including gent to the USPTO. Time will the amount of time you rhis burden, should be sent to ffice, U.S. Department of the END FEES OR COMPLE for Patents, Alexandria, Virginal Products of the USPTO FEES OR COMPLE for Patents, Alexandria, Virginal registers.	ed) will not be accept, or the assigne tent and Trademark 1.311. The inform le (and by the USI 22 and 37 CFR 1.1 thering, preparing, I vary depending the equire to complete of the Chief Inform of Commerce, Al TED FORMS TO (inia 22313-1450.	e or other party, to office. ation is required PTO to process) 4. This collection and submitting apon the individe this form and lation Officer, U exandria, Virgin THIS ADDRES	01 FC:1501 02 FC:1504 03 FC:8001	ANOHDAF2 0000 1330.00 300.00 30.00	DA DA	10071699	



VERTEX PHARMACEUTICALS INCORPORATED

130 Waverly Street Cambridge, MA 02139-4242 Tel. 617.444.6100 Fax 617.444.6680 www.vrtx.com



To	Examiner Deepak R. Rao Group Art Unit: 1624
Company	USPTO
FAX	(703) 746-4000
From	Andrea L. C. Robidoux
Date	December 30, 2003
Subject	Application No. 10/071,699
	Attorney Docket No. VPI/01-103 US
Pages to Follow	3

Message or Comment

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence, and any documents referred to as attached hereto, is/are being transmitted to the United States Patent and Trademark Office, Facsimile Number: (703) 746-4000 on this 31st day of December 2003.

Karen DiRocco

If any problems occur with this fax transmittal, please call (617) 444-6731 immediately.

FAX Number (617) 444-6483 Legal Department

The information and the documents transmitted by this telecopy are privileged and contain confidential information intended only for the person (s) names above. Any other distribution, copying or disclosure is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original to us without making a copy.